LH news

Labcorp announced Chief Financial Officer Julia Wang will speak at the UBS Global Healthcare Conference on November 10. This leadership engagement provides insight into the company's strategy in a major healthcare forum.

Labcorp reported a 6.9% increase in Q3 2026 revenue to $3.81 billion and 14.5% growth in adjusted EPS, prompting an increase in full-year guidance and the approval of a new melanoma companion diagnostic.

Labcorp Holdings Inc. declared a quarterly cash dividend of $0.72 per share, payable on December 11, 2026. The company paid out over $750 million tests in 2025, and supported 85% of new FDA approved drugs.

Labcorp will announce financial results for the third quarter of 2026 before the market opens on Oct. 28. The company plans to host a live webcast to discuss these results.

Labcorp disclosed a long-term outlook targeting 5% to 8% annualized revenue growth and margin expansion through 2029. The announcement is significant for the diagnostics sector and underscores the company's strategic alignment with scientific innovation.

Labcorp announced its executives will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference. This participation highlights the company's focus on engaging with the healthcare investment community.

Labcorp announced a virtual Investor Day to present its go-forward strategy and long-term outlook. The event is expected to provide key insights for investors regarding the company's future direction.

Labcorp beat quarterly earnings expectations and raised 2026 guidance, citing growth in core business and oncology. The company announced a $1.0 billion increase in its share repurchase program.

Labcorp's board approved a quarterly cash dividend of $0.72 per share payable on September 11. This announcement underscores the company's continued commitment to returning capital to shareholders.

Labcorp will release its second quarter 2026 financial results on July 30. This announcement provides market participants with the specific timing to anticipate key financial disclosures and guidance.

Labcorp will present at the 2026 Jefferies Global Healthcare Conference in New York on June 3, with a live webcast available on its investor relations website. The presentation is a routine investor engagement activity with no material business impact.